Marks Group Wealth Management Inc Has $19.03 Million Stake in Stryker Corporation $SYK

Marks Group Wealth Management Inc lowered its stake in Stryker Corporation (NYSE:SYK) by 3.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,475 shares of the medical technology company’s stock after selling 1,936 shares during the period. Stryker accounts for approximately 1.8% of Marks Group Wealth Management Inc’s holdings, making the stock its 3rd biggest holding. Marks Group Wealth Management Inc’s holdings in Stryker were worth $19,029,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Clayton Financial Group LLC purchased a new position in shares of Stryker during the third quarter valued at about $26,000. Elevation Point Wealth Partners LLC bought a new stake in Stryker during the 2nd quarter valued at approximately $28,000. Kilter Group LLC purchased a new position in shares of Stryker during the 2nd quarter worth approximately $29,000. Howard Hughes Medical Institute bought a new position in shares of Stryker in the 2nd quarter worth approximately $29,000. Finally, ANTIPODES PARTNERS Ltd purchased a new position in shares of Stryker in the 3rd quarter valued at approximately $34,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Up 2.0%

NYSE:SYK opened at $380.15 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The firm has a market cap of $145.48 billion, a P/E ratio of 45.26, a P/E/G ratio of 2.22 and a beta of 0.87. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $404.87. The firm has a 50-day simple moving average of $360.05 and a two-hundred day simple moving average of $368.82.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. The firm had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.01 earnings per share. Analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 0.9%. Stryker’s payout ratio is currently 41.90%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Stryker in a research note on Monday, December 22nd. Raymond James Financial raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target for the company in a research report on Tuesday, January 6th. TD Cowen lowered shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 price objective on the stock. in a research note on Monday, January 26th. Finally, Barclays reaffirmed an “overweight” rating and set a $469.00 target price on shares of Stryker in a research note on Monday, February 2nd. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $426.94.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.20% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.